Highest-materiality recent filing
Three Class III directors re-elected: Reyes (179,416 for), Favorito (176,821), Gorgas (171,567); broker non-votes 937,382.
Artelo Biosciences launches $6.53M ATM program; Craft Capital files FINRA claim for $880K
Entered at-the-market offering agreement with H.C. Wainwright to sell up to $6.53M of common stock, with 3.0% commission.
Artelo Biosciences terminates ATM offering agreement with R.F. Lafferty; minimal prior sales
Termination notice issued May 11, 2026; effective May 18, 2026.
Artelo Biosciences regains Nasdaq compliance; monitored for one year
Nasdaq confirmed compliance with Equity Rule (≥$2.5M stockholders' equity) and Annual Meeting Rule.
Artelo Biosciences closes $11M private placement; expects to regain Nasdaq compliance
Gross proceeds $11.0M from sale of 3.19M common shares (or pre-funded warrants) and 6.38M common warrants at $3.45/unit.
Artelo expands ART27.13 development for muscle preservation with GLP-1 therapies
ART27.13 to be evaluated as companion therapy to prevent muscle loss in patients on GLP-1 receptor agonists for weight reduction.
Artelo Biosciences raises $310k via 12% bridge notes with default conversion feature
Issued two 12% bridge notes totaling $350,300 principal ($237,300 Vanquish + $113,000 Boot) for net proceeds of $310,000 after $40,300 OID.
Artelo Biosciences completes 1-for-3 reverse split; FY2025 net loss $12.9M, going concern
1-for-3 reverse stock split effective March 10, 2026; shares reduced from 2.1M to ~708k.
Artelo Biosciences effects 1-for-3 reverse stock split effective March 10, 2026
Reverse split ratio 1-for-3; outstanding shares reduced from 2,124,772 to ~708,258.
Artelo Biosciences gets Nasdaq panel exception to cure listing deficiencies by March 30
Panel granted exception to regain compliance with $2.5M stockholders' equity rule by March 30, 2026.
Artelo enters up to $50M equity purchase facility with Square Gate; issues 292K commitment shares
Equity Purchase Agreement with Square Gate provides up to $25M initially, expandable to $50M at company's option.
Quorum achieved with 1,017,816 of 2,018,746 outstanding shares (50.4%) at reconvened meeting on Jan 30, 2026.
Artelo Biosciences receives Nasdaq delisting notice for missing annual meeting deadline
Nasdaq notified Artelo on Jan 14, 2026 of non-compliance with the Annual Meeting Rule (5620(a)).
Artelo Biosciences adjourns 2025 annual meeting due to insufficient quorum; reconvenes Jan 30, 2026
Annual meeting convened Dec 31, 2025 and adjourned without conducting business due to lack of quorum.
Artelo Biosciences receives Nasdaq delisting notice; plans to appeal
Received delist determination on Nov 19, 2025 for non-compliance with equity rule (min $2.5M stockholders' equity).
Board amended bylaws on November 10, 2025, effective immediately.
Artelo Biosciences issues $690K convertible notes and warrants to investors including directors
Issued convertible notes aggregating $690,154.69 principal to investors, converting May 2025 notes.
Artelo Biosciences appoints Mark Spring as CFO effective November 1, 2025
Spring replaces Gregory Gorgas as principal financial officer and treasurer; Gorgas remains CEO.
Artelo Biosciences settles with activist investor Daniel Farb; he withdraws board nominations
Daniel S. Farb and affiliates irrevocably withdraw director nominations for 2025 annual meeting (letter dated Sept 19, 2025).
Artelo Biosciences closes $2M public offering of common stock and pre-funded warrants
Gross proceeds ~$2M from 441,210 shares at $4.40/share and 13,335 pre-funded warrants at $4.399/warrant (ex. price $0.001).
Artelo raises $0.25M from partial over-allotment exercise after $3M offering
Underwriter exercised over-allotment option for 57,914 shares at $4.40/share, generating ~$0.25M gross proceeds.
Board eliminated stockholders' right to act by written consent, effective immediately.
Artelo Biosciences closes $3M public offering of common stock and pre-funded warrants
Closed underwritten offering of 640,924 shares at $4.40/share and 40,894 pre-funded warrants at $4.399 each.
Interim Phase 2 CAReS: ART27.13 patients gained 6.38% mean body weight vs placebo loss of -5.42% at 12 weeks.
Artelo shareholders approve 60x increase in common stock authorization; preferred increase fails
Common stock authorization increased from 8.3M to 500M shares; voted 325,388 For vs 38,731 Against.
Artelo Biosciences terminates private placement and ABK Labs consulting pact
Terminated Aug 1 Securities Purchase Agreement for 593,252 shares and 2,126,809 warrants; no securities issued.
Artelo Biosciences Enters Consulting Agreement with ABK Labs for Digital Asset Strategy
Artelo signed a 4-year consulting agreement with ABK Labs for strategic advisory on digital asset strategy, business development, and investor relations.
Artelo raises ~$9.5M private placement to buy Solana; gets UK MHRA nod for Phase 1 trial
Gross proceeds ~$9.475M from 593,252 shares at $10.20 plus prefunded warrants; also issues Market Priced ($10.20) and $50.00 warrants.
Artelo Biosciences enters $6.5M at-the-market equity offering with R.F. Lafferty
Agreement with R.F. Lafferty & Co. to sell up to $6.5M of common stock via ATM program.
1-for-6 reverse split effective June 13, 2025, reducing outstanding shares from 3,280,000 to ~546,667.
Artelo raises $1.425M in private placement; to use $250k proceeds to buy SOL
Gross proceeds ~$1.425M from private placement of shares, pre-funded warrants, and warrants.
Artelo Biosciences completes 1-for-6 reverse stock split; Nasdaq compliance regained
Effective 12:01 a.m. ET June 13, 2025; each 6 pre-split shares combine into 1 post-split share; outstanding shares reduced from 3,280,000 to ~546,667.
Artelo Biosciences notified by Nasdaq of equity deficiency; $652K vs $2.5M minimum
As of March 31, 2025, stockholders' equity was $652,000, below the $2.5M minimum required by Nasdaq Rule 5550(b)(1).
Artelo Biosciences raises $900k via convertible notes with 12% interest and warrants
Closed $900,000 convertible note offering; directors and management purchased $200,000 of the notes.
Received Nasdaq notice on April 23, 2025 for non-compliance with $1.00 minimum bid price requirement.
Artelo Biosciences announces annual meeting results; re-elects directors and ratifies auditor
40.9% of shares represented at Dec 20, 2024 annual meeting (1,319,986 of 3,227,700 outstanding).
Artelo Biosciences reprices options to $1.55, resets vesting over 3 years for retention
Compensation Committee amends options with exercise price ≥$1.99 to new price of $1.55 (Feb 28 closing).
Artelo Biosciences increases CEO base salary to $500,000
CEO Gregory D. Gorgas annual base salary raised from $475,000 to $500,000 effective August 4, 2023.
Artelo Biosciences annual meeting elects all 7 directors and ratifies auditor
Quorum of 39.2% (1,120,239 shares represented) at June 30, 2023 meeting.
Artelo Biosciences adopts classified board with staggered three-year terms
Board amended bylaws to create three classes of directors with staggered three-year terms.
Artelo Biosciences confirms no deposits or accounts at Silicon Valley Bank
Company states it holds no deposits, securities, or accounts at SVB.
Artelo Biosciences adopts classified board, advance notice provisions, triennial say-on-pay vote
Board adopted amended bylaws creating a classified board with three classes and staggered three-year terms as of September 16, 2022.
Artelo Biosciences regains Nasdaq minimum bid price compliance
Received Nasdaq letter confirming compliance with Listing Rule 5550(a)(2) on August 24, 2022.
Net loss $2.4M ($0.87/share) in Q2 2022 vs $2.3M ($1.45/share) in Q2 2021; operating expenses $2.4M.
All seven director nominees re-elected; Gregory Gorgas received 4,577,152 votes for.
Artelo Biosciences enters $20M common stock purchase agreement with Lincoln Park Capital
Company may sell up to $20M of common stock over 36 months at discounts of 3-5% to market price.
Artelo Biosciences gets second 180-day Nasdaq extension to meet $1 minimum bid price
Nasdaq granted second 180-day period until September 12, 2022 to regain compliance with bid price rule.
Artelo Bio CAReS trial on track; board approves 2022 goals, cuts quorum to 35%
CEO Gorgas eligible for 2022 bonus based on goals: clinical (40%), pre-clinical (35%), financial (25%).
Artelo Biosciences grants CEO Gregory Gorgas option for 1.355M shares at $0.63
Option to purchase 1,355,000 shares of common stock at exercise price of $0.63 per share.
Received Nasdaq notice on Sept 13, 2021 for failure to meet $1.00 minimum bid price (Listing Rule 5550(a)(2)).
the untimely and unexpected death of Mr. John W. Beck on July 20, 2021.
Max materiality 0.80 · Median 0.55 · Most common event other_material